These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29611175)

  • 1. Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center.
    Grabowski M; Gawałko M; Michalak M; Cacko A; Kowara M; Kołodzińska A; Januszkiewicz Ł; Balsam P; Vitali Serdoz L; Winter J; Opolski G
    Cardiol J; 2019; 26(4):360-367. PubMed ID: 29611175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?
    Botto GL; Forleo GB; Capucci A; Solimene F; Vado A; Bertero G; Palmisano P; Pisanò E; Rapacciuolo A; Infusino T; Vicentini A; Viscusi M; Ferrari P; Talarico A; Russo G; Boriani G; Padeletti L; Lovecchio M; Valsecchi S; D'Onofrio A;
    Europace; 2017 Nov; 19(11):1826-1832. PubMed ID: 28011803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polish single-centre follow-up of subcutaneous implantable cardioverter-defibrillator (S-ICD) systems implanted for the prevention of sudden cardiac death.
    Kempa M; Budrejko S; Sławiński G; Królak T; Lewicka E; Raczak G
    Kardiol Pol; 2018; 76(2):452-458. PubMed ID: 29350391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Sudden Cardiac Death: Focus on the Subcutaneous Implantable Cardioverter-Defibrillator.
    Adduci C; Palano F; Silvetti G; Cosentino P; Francia P
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):291-297. PubMed ID: 32519207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.
    Migliore F; Mattesi G; De Franceschi P; Allocca G; Crosato M; Calzolari V; Fantinel M; Ortis B; Facchin D; Daleffe E; Fabris T; Marras E; De Lazzari M; Zanon F; Marcantoni L; Siciliano M; Corrado D; Iliceto S; Bertaglia E; Zecchin M
    J Cardiovasc Electrophysiol; 2019 Jun; 30(6):854-864. PubMed ID: 30827041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.
    Probst V; Boveda S; Sadoul N; Marquié C; Chauvin M; Mondoly P; Gras D; Jacon P; Defaye P; Leclercq C; Anselme F
    Arch Cardiovasc Dis; 2020 May; 113(5):359-366. PubMed ID: 32334981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Subcutaneous implantable cardioverter-defibrillator in prevention of sudden cardiac death in Poland - opinion paper endorsed by the Polish Cardiac Society Working Group on Heart Rhythm].
    Ptaszyński P; Grabowski M; Kowalski O; Kempa M; Mitkowski P; Przybylski A; Sterliński M
    Kardiol Pol; 2017; 75(10):1057-1060. PubMed ID: 29057442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Subcutaneous Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death　- Primary Japanese Experience.
    Sasaki S; Tomita H; Tsurugi T; Ishida Y; Shoji Y; Nishizaki K; Kinjo T; Endo T; Nishizaki F; Hanada K; Sasaki K; Horiuchi D; Kimura M; Higuma T; Okamatsu H; Tanaka Y; Koyama J; Okumura K
    Circ J; 2018 May; 82(6):1546-1551. PubMed ID: 29643282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subcutaneous implantable cardioverter-defibrillator: A tertiary center experience.
    Khazen C; Magnusson P; Flandorfer J; Schukro C
    Cardiol J; 2019; 26(5):543-549. PubMed ID: 29718532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantation of the Micra transcatheter pacing system: Single Polish center experience with the real costs of hospitalization analysis.
    Grabowski M; Michalak M; Gawałko M; Gajda S; Cacko A; Januszkiewicz Ł; Kołodzińska A; Mitkowski PP; Duray GZ; Opolski G
    Cardiol J; 2020; 27(1):47-53. PubMed ID: 30155871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland.
    Kempa M; Opielowska-Nowak B; Budrejko S; Raczak G
    Cardiol J; 2023; 30(2):214-220. PubMed ID: 35975797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: Pediatric Single-Center Experience.
    Wieniawski P; Buczyński M; Grabowski M; Winter J; Werner B
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.
    Nichols CI; Vose JG; Mittal S
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.